405224-22-8

Basic information

• Product Name: 5-BROMO-3-CYANO-2-HYDROXYPYRIDINE
• Synonyms: 5-BROMO-3-CYANO-2-HYDROXYPYRIDINE;5-BROMO-3-CAYNO-2(1H)-PYRIDINONE;5-BROMO-2-HYDROXY-3-PYRIDINECARBONITRILE;5-BROMO-2-HYDROXYNICOTINONITRILE;5-Bromo-3-cyano-2-hydroxypyridine 98%;5-Bromo-3-cyano-2(1H)-pyridinone;5-bromo-2-hydroxypyridine-3-carbonitrile;5-bromo-2-hydroxynicotino...
• CAS NO: 405224-22-8
• Molecular Formula: C₆H₃BrN₂O
• Molecular Weight: 199
• Product Categories: blocks;Bromides;Carboxes;Pyridines;alcohol|cyanide| alkyl bromide
• Mol File: 405224-22-8.mol
• Article Data: 12

Chemical Properties

• Melting Point: 219-221
• Boiling Point: 292.126 °C at 760 mmHg
• Flash Point: 130.473 °C
• Appearance: /
• Density: 1.844 g/cm³
• Vapor Pressure: 0.00187mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: Keep Cold
• PKA: 6.87±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-3-CYANO-2-HYDROXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-CYANO-2-HYDROXYPYRIDINE(405224-22-8)
• EPA Substance Registry System: 5-BROMO-3-CYANO-2-HYDROXYPYRIDINE(405224-22-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 405224-22-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-3-cyano-2-hydroxypyridine is a chemical compound with the molecular formula C6H3BrN2O. It is a highly reactive and versatile compound used in the pharmaceutical and agrochemical industries. The presence of a bromine atom, a cyano group, and a hydroxy group in its structure makes it suitable for various chemical reactions and synthesis processes. It is commonly utilized as a building block in the production of pharmaceutical drugs and agrochemicals. Its structure and properties make it a valuable intermediate in the synthesis of various compounds with biological and industrial applications. Additionally, it is used as a substrate in chemical research and development. However, it is important to handle this compound with caution due to its reactivity and potential hazards.

InChI:InChI=1/C6H3BrN2O/c7-5-1-4(2-8)6(10)9-3-5/h1,3H,(H,9,10)

Upstream product

• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 20577-27-9 2-hydroxy-3-cyanopyridine 
• 20577-27-9 pyrid-2-one-3-carbonitrile 

Downstream Products

• 405224-23-9 5-bromo-2-chloropyridine-3-carbonitrile 
• 35982-98-0 C₁₂H₇ClN₂O 
• 1426959-54-7 C₁₈H₁₂N₂O 
• 1426959-48-9 C₁₂H₈N₂OS 
• 1426959-49-0 C₁₃H₁₀N₂OS 
• 1426959-50-3 C₁₅H₁₄N₂OS 
• 1426959-51-4 C₁₇H₁₈N₂OS 
• 1426959-52-5 C₁₂H₇BrN₂OS 
• 1426959-53-6 C₁₂H₉N₃OS 
• 1426959-55-8 C₂₂H₂₀N₂OS 

Relevant articles and documents

Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors

Anaplastic lymphoma kinase (ALK) has been recognised as a promising molecular target of targeted therapy for NSCLC. We performed SAR study of pyrazolo[3,4-b]pyridines to override crizotinib resistance caused by ALK-L1196M mutation and identified a novel and potent L1196M inhibitor, 10g. 10g displayed exceptional enzymatic activities (50) against ALK-L1196M as well as against ALK-wt. In addition, 10g is an extremely potent inhibitor of ROS1 (50) and displays excellent selectivity over c-Met. Moreover, 10g strongly suppresses proliferation of ALK-L1196M-Ba/F3 and H2228 cells harbouring EML4-ALK via apoptosis and the ALK signalling blockade. The results of molecular docking studies reveal that, in contrast to crizotinib, 10g engages in a favourable interaction with M1196 in the kinase domain of ALK-L1196M and hydrogen bonding with K1150 and E1210. This SAR study has provided a useful insight into the design of novel and potent inhibitors against ALK gatekeeper mutant.

Pyrazolopyridine or indazole derivatives as protein kinase inhibitors

The present invention relates to novel pyrazolopyridine or indazole derivatives having inhibitory activity against protein kinases or pharmaceutically acceptable salts thereof. Since compounds of the present invention have excellent inhibitory activity against to protein kinases, for example, ABL, ACK1, ALK, Aurora A, Aurora B, Aurora C, BLK, BMX/ETK, BRSK1, BTK, c-Src, CAMKK, CDK1, CDK2, CDK5, CLK, DDR, DYRK1B, EPHA, EPHB, FAK/PTK2, FER, FES/FPS, FGFR, FGR, FLT3, FLT4/VEGFR3, FMS, FRK/PTK5, FYN, GSK3b, HCK, IGF1R, IR, IRAK1, IRR/INSRR, ITK, JAK2, KHS/MAP4K5, LCK, LYN, PHKg, PLK4/SAK, PYK2, RET, ROS/ROS1, TIE2/TEK, TRK, TXK, TYK, YES/YES1, and the like, the compounds are useful for treatment and prevention of various kinds of cancer diseases.

Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461

Abstract Two series of novel 1,5-naphthyridine and 1,6-naphthyridine derivatives were designed and synthesized based on the c-Met kinase inhibitor MK-2461 under the guidance of scaffold hopping strategy. All were tested on c-Met kinase and in vitro anti-tumor activities against Hela and A549 cell lines. The results indicated that 1,6-naphthyridine was a more promising c-Met inhibitory structure core compared with 1,5-naphthyridine. Among them, 26b and 26c showed the best enzymic and cytotoxic activities. The western blot experiments implied that the cytotoxic activity of 26c might be partially through suppressing the phosphorylation of c-Met kinase.